TY - JOUR
T1 - Life-Threatening Serotonin Syndrome Precipitated by Discontinuation of Serotonin-Dopamine Antagonist in the Presence of Serotonergic Agents
T2 - A Case Report
AU - Ishida, Takuto
AU - Uchida, Hiroyuki
AU - Kaneko, Satoru
AU - Sugiyama, Kazuhiro
AU - Hamabe, Yuichi
AU - Mimura, Masaru
AU - Suzuki, Takefumi
N1 - Funding Information:
Address correspondence and reprint requests to Takuto Ishida, MD, PhD, Tertiary Emergency Medical Center, Tokyo Metropolitan Bokutoh Hospital 4-23-15 Kotohbashi, Sumida-ku, Tokyo 130-8575, Japan; E‐mail: t_ishi_2750@yahoo.co.jp Conflicts of Interest and Source of Funding: T.I. has received a manuscript fee from Dainippon Sumitomo Pharma within the past 3 years. H.U. has received grants from Eisai, Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, and Meiji-Seika Pharmaceutical and speaker's honoraria from Otsuka Pharmaceutical, Dainippon-Sumitomo Pharma, Meiji-Seika Pharmaceutical, Eli Lilly, Yoshitomi Yakuhin, and MSD within the past 3 years. M/M. has received grants or consultant fees from Daiichi Sankyo, Eisai, Pfizer, Takeda Yakuhin, Tsumura, Tanabe Mitsubischi, and Shionogi and received speaker's honoraria from Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Janssen Pharmaceutical, MSD, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin, within the past 3 years. T.S. has received manuscript or speaker's fees from Dainippon Sumitomo Pharma, Eli Lilly, Elsevier Japan, Janssen Pharmaceutical, Meiji Seika Pharma, Otsuka Pharmaceutical, Wiley Japan, and Yoshitomi Yakuhin within the past 3years. The other authors have no conflicts of interest to declare.
Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Introduction Serotonin syndrome is caused by excessive activation of serotonin (5-hydroxytryptamine [5-HT]) neurotransmission. Although the discontinuation of antipsychotics with 5-HT2 receptor antagonistic characteristics could theoretically result in serotonin syndrome, there have been very few reports on the syndrome thus far. Case Presentation A 75-year-old woman with somatoform disorder was transferred to our emergency room because of pyrexia, unconsciousness, and myoclonus with hyperreflexia. She had been taking milnacipran and perospirone for 10 years and had started taking duloxetine 2 months before the event. Thereafter, she suffered diaphoresis, gait disturbance, and tremor. Her psychiatrist advised her to stop taking perospirone, because of suspicion of extrapyramidal symptoms, a day before admission. The clinical diagnosis of serotonin syndrome was made based on her symptoms while using serotonergic agents. Her symptoms were so severe that she was transferred to the intensive care unit, where supportive care was successful. Conclusions Discontinuation of antipsychotics that are 5-HT2 receptor antagonists may lead to serotonin syndrome in patients who take serotonergic agents. As extrapyramidal symptoms and serotonin toxicity share some clinical features, detailed drug history and physical examination are necessary for successful treatment.
AB - Introduction Serotonin syndrome is caused by excessive activation of serotonin (5-hydroxytryptamine [5-HT]) neurotransmission. Although the discontinuation of antipsychotics with 5-HT2 receptor antagonistic characteristics could theoretically result in serotonin syndrome, there have been very few reports on the syndrome thus far. Case Presentation A 75-year-old woman with somatoform disorder was transferred to our emergency room because of pyrexia, unconsciousness, and myoclonus with hyperreflexia. She had been taking milnacipran and perospirone for 10 years and had started taking duloxetine 2 months before the event. Thereafter, she suffered diaphoresis, gait disturbance, and tremor. Her psychiatrist advised her to stop taking perospirone, because of suspicion of extrapyramidal symptoms, a day before admission. The clinical diagnosis of serotonin syndrome was made based on her symptoms while using serotonergic agents. Her symptoms were so severe that she was transferred to the intensive care unit, where supportive care was successful. Conclusions Discontinuation of antipsychotics that are 5-HT2 receptor antagonists may lead to serotonin syndrome in patients who take serotonergic agents. As extrapyramidal symptoms and serotonin toxicity share some clinical features, detailed drug history and physical examination are necessary for successful treatment.
KW - antidepressant
KW - perospirone
KW - second-generation antipsychotics
KW - serotonin syndrome
UR - http://www.scopus.com/inward/record.url?scp=85084721731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084721731&partnerID=8YFLogxK
U2 - 10.1097/WNF.0000000000000385
DO - 10.1097/WNF.0000000000000385
M3 - Article
C2 - 32217863
AN - SCOPUS:85084721731
SN - 0362-5664
VL - 43
SP - 81
EP - 83
JO - Clinical Neuropharmacology
JF - Clinical Neuropharmacology
IS - 3
ER -